for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



This study is designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in subjects with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least 1 prior line of therapy. The study will consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the subjects will be divided into 2 cohorts, subjects positive for t(11;14) translocation and subjects negative for t(11;14) translocation.

Official Title

A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma


Multiple Myeloma Cancer Multiple Myeloma (MM) Relapsed or Refractory (R/R) venetoclax pomalidomide dexamethasone Neoplasms, Plasma Cell Dexamethasone acetate Thalidomide BB 1101


You can join if…

Open to people ages 18 years and up

  • Relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the subject's last treatment regimen.
  • Measurable disease as described in the protocol.
  • Received at least 1 prior line of therapy, as described in the protocol.
  • Must meet prior antimyeloma treatment parameters, as described in the protocol, and includes:
  • Received at least 2 consecutive cycles of lenalidomide or a lenalidomide containing regimen
  • Refractory to lenalidomide
  • Exposed to a proteasome inhibitor (PI) alone or in combination with another agent.
  • Had a response of partial response (PR) or better to prior therapy based on the investigator's determination of response as defined by International Myeloma Working Group (IMWG) criteria.
  • Has t(11;14) status as described in the protocol and meets the following criteria:
  • For Part 1: MM subjects independent of cytogenetic profile.
  • For Part 2, Arm A: subject must be t(11;14) positive.
  • For Part 2, Arm B: subject must be t(11;14) negative.
  • An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Adequate kidney, liver and hematologic laboratory values.

You CAN'T join if...

  • History of severe osteoporosis with previous spontaneous fractures.
  • Untreated brain or meningeal metastases.
  • Grade 2 or higher peripheral neuropathy (only applies to subjects who would receive taxane therapy).
  • Unresolved Grade 2 or higher toxicities related to previous anticancer therapy.
  • Known active infection of hepatitis B or C, or human immunodeficiency virus.
  • Recent history (within 6 months) of congestive heart failure, ischemic cardiovascular event, pericardial effusion, or pericarditis.
  • Subject used medications including investigational drugs, steroids, cytochrome P450(CYP)3A inhibitors, or live vaccines within the time frames as described in the protocol.


  • Univ California, San Francisco /ID# 204524 not yet accepting patients
    San Francisco California 94143-2204 United States
  • Oregon Health and Science University /ID# 205582 not yet accepting patients
    Portland Oregon 97239-3098 United States


accepting new patients
Start Date
Completion Date
Phase 2
Study Type
Last Updated